CGEM- Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. (CGEM) has 8 insiders with recent SEC Form 4 filings, including 11 buys and 15 sells. CGEM is classified in the Biotechnology industry within the Health Care sector.
Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 8.96M | $160.89M | - | |
| CEO | 420.7K | $7.55M | - | |
| Other | 169.5K | $3.04M | - | |
| Other | 135.4K | $2.43M | - | |
| Other | 132.6K | $2.38M | - |
Activity
Buys and sells only
Transactions
10 filings · page 8
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 19, 2022 | Savill Corrine67 | Acting Chief Business Officer | Sell | 20,000 | $15.18 | $303,593.28 | -6.0% | -18.0% | -27.7% | |
| Jul 11, 2022 | Savill Corrine67 | Acting Chief Business Officer | Sell | 40,000 | $13.33 | $533,304.00 | -10.5% | -5.7% | -25.1% | |
| Jun 23, 2022 | F2 Bioscience I 2017 Ltd57 | 10% Owner | Sell | 101,903 | $12.80 | $1,304,816.42 | -5.6% | -9.2% | -6.8% | |
| Jun 6, 2022 | Ahmed Nadim49 | President And CEO | Buy | 8,090 | $12.40 | $100,316.00 | New | +3.3% | +0.1% | |
| Jun 1, 2022 | Bvf Partners L P/il60 | 10% Owner | Buy | 751,396 | $11.00 | $8,264,905.16 | +11.3% | +11.5% | -10.4% | |
| May 16, 2022 | F2 Vision Scs60 | 10% Owner | Sell | 418,738 | $9.66 | $4,045,791.27 | -7.1% | +30.1% | -16.1% | |
| May 13, 2022 | Bvf Partners L P/il60 | 10% Owner | Buy | 1,109,900 | $9.07 | $10,063,936.50 | +9.4% | +25.0% | -8.1% | |
| Apr 1, 2022 | Bvf Partners L P/il60 | 10% Owner | Buy | 276,000 | $10.75 | $2,966,972.40 | +5.5% | +16.7% | -6.9% | |
| Oct 18, 2021 | Michaelson Jennifer65 | See Remarks | Sale+OE | 4,000 | $21.42 | $85,669.20 | -5.4% | -39.3% | -39.9% | |
| Oct 15, 2021 | Trigilio Jeffrey51 | Chief Financial Officer | Sale+OE | 8,000 | $25.00 | $200,000.00 | -78.0% | -46.6% | -49.5% |